Latest news with #AssistedReproductive
Associated Press
17-06-2025
- Health
- Associated Press
Announcing The World Fertility Awards: Celebrating Global Change Agents Advancing Fertility Awareness, Innovation, and Inclusion
- This event recognizes the people supporting the future of fertility in three areas: Access & Awareness, Innovation & Technology, and Equity & Inclusion - NEW YORK, N.Y., June 17, 2025 (SEND2PRESS NEWSWIRE) — Pregnantish, the first global media platform dedicated to helping people navigate their fertility, announces the inaugural World Fertility Awards at The Times Center in New York City in December. Award nominations are now open at and will be accepted until August 1, 2025. The World Fertility Awards (WFAs), produced by pregnantish, will convene patients, advocates, medical professionals, public personalities, social influencers, media outlets, industry representatives, and digital health leaders working together to transform the future of family building around the world by celebrating progress and fostering momentum to advance fertility awareness, access, and care. Supported by host committees across seven global regions, the WFAs will reach millions of people worldwide who are struggling to conceive and/or can't access necessary treatment to build their families. 'At least 1 in 6 are experiencing infertility globally, according to the World Health Organization – and that's just what's reported,' says Andrea Syrtash, Relationships Author and Founder of pregnantish and the WFAs. 'With a global decline in fertility happening and dystopian fertility headlines trending in the news, the World Fertility Awards were conceived to raise awareness about infertility, recognize the heroes who develop life-changing healthcare, and amplify the stories of fertility and modern family-building.' Pregnantish is uniquely positioned to host this event, having reached over one billion globally since inception with high quality content, sold-out live events, scientifically published research on the patient journey, and education that's helped support patients and providers as they work together to build families with the help of Assisted Reproductive Technology. This event recognizes the people supporting the future of fertility in three areas: Access & Awareness, Innovation & Technology, and Equity & Inclusion. The WFAs has the support of global ambassadors which includes thought leaders from medicine, advocacy, journalism, technology, finance, and entertainment sectors. Members include respected fertility specialists like Dr. Rodrigo De Rosa (Brazil), Dr. Prati Sharma (Canada), Dr. Lusanda Shimange-Matsose, (South Africa) and US advocates like Sarah Kennedy Ellis, VP at Google, David Sable, Life Sciences Portfolio Manager, Eboni K. Williams, TV Host & Author, and Elizabeth Jordan Carr, the first U.S. IVF baby. Dr. Lucky Sekhon, co-chair of the US Host Committee and Infertility Specialist at RMA of New York — a practice within the US Fertility network, who is a sponsor of the event — shares: 'The World Fertility Awards are a recognition of the human stories and groundbreaking science that shape the field of reproductive medicine. Amplifying these voices is deeply meaningful because it reflects our shared commitment to innovation, collaboration, and equitable access to care.' Dr. Prateek Makwana, Director at Vasundhara Hospital and Co-Chair of the South Asia Host Committee notes, 'Infertility is on the rise in India. While people now seek medical opinion relatively quickly when trying to conceive, there is still a huge gap in how society sees and portrays infertility. The WFAs help with recognising people and amplifying real voices, breaking cultural taboos, and inspiring open conversations.' Gretchen Adcock, Head of Sales at Lending Club Patient Solutions, felt that it was important to support an event showing the need for people to access fertility treatments: 'Navigating treatment costs can be overwhelming, we know, and I'm glad to work for a company that offers budget-friendly plans and a straightforward application process. People shouldn't delay treatment because of cost; but sadly that's a reality for some in the US today.' Ola Taiwo, host of Africa's first fertility podcast and Co-Chair of the Africa Host Committee, says, 'In Nigeria, infertility is often misunderstood—especially for women. It's time to break the silence, challenge the shame, and recognize infertility for what it truly is: a medical condition, not a moral failure. We need more awareness, access, empathy, and support—and a complete shift in how we talk about it.' Learn more (Video/YouTube): Visit to submit award nominations and to take the pledge. To get involved as a sponsor, contact [email protected]. Initial sponsors include US Fertility, LendingClub, LabCorp, IVI RMA, EMD Serono Canada, among others. About Pregnantish Inc. Pregnantish launched in 2017 as the first media platform dedicated to elevating the conversation about fertility with the help of Assisted Reproductive Technology. The company is home to Pregnantish Insights, a division dedicated to researching fertility experiences with the goal of bridging the gap between patients and their providers. Today, a diverse cross-section of people come to pregnantish to find the content, community and events they need to travel their own fertility journey. Founder Andrea Syrtash is an internationally recognized relationship and sexual health expert, author, and fertility advocate who uniquely understands the relationship between patients and the products and services they seek. Learn more: Follow @pregnantish for more: Press inquiries: [email protected] Image link for media: Image caption: Announcing The World Fertility Awards. NEWS SOURCE: Pregnantish Inc. Keywords: Fertility and IVF, World Fertility Awards, Pregnantish Inc, patients, advocates, medical professionals, NEW YORK, N.Y. This press release was issued on behalf of the news source (Pregnantish Inc.) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P127038 APNF0325A To view the original version, visit: © 2025 Send2Press® Newswire, a press release distribution service, Calif., USA. RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT. Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.
The Hindu
15-06-2025
- Health
- The Hindu
MNCU, ART centre, ECRC opened at Coimbatore Medical College Hospital
Health Minister Ma. Subramanian on Sunday inaugurated a Mother – Newborn Care Unit (MNCU) and an Assisted Reproductive Technology (ART) centre at the Coimbatore Medical College Hospital (CMCH). The MNCU built at a cost of ₹86 lakh has 10 beds for mothers with attached facilities for newborns. This will ensure treatment of ailing postnatal mothers or newborns within the same space, without separating them. The Minister said that the ART centre that has come up at the tertiary level government hospital at a cost of ₹16.3 lakh will help couples from poor economic backgrounds undergo in vitro fertilization (IVF) treatment, which in private facilities cost ₹10 to ₹12 lakh. Already such centres have come up at the Institute of Obstetrics and Gynaecology in Egmore and the Government Mohan Kumaramangalam Medical College Hospital, Salem, he said. Mr. Subramanian said that the government, as announced earlier, has launched provision of somatrogon, a medication for growth hormone deficiency in children, at a cost of ₹13.28 crore. At a time, each beneficiary will be given the medication, which comes as a disposable injection pen, for five weeks that cost around ₹60,000. The medical will continue as prescribed by doctors. The Minister also inaugurated an Emergency Care and Recovery Centre (ECRC) at the hospital, which is a 15-bedded facility for the care and treatment of homeless persons and those who are found on streets, requiring immediate medical attention. He said 16 ECRCs are functioning across the State with the support of non-governmental organisations. He also distributed free spectacles to 50 persons aged above 50, who underwent eye check-up camps organised by the district administration in collaboration with Rotary International at Thondamuthur, Madukkarai, Negamam, Karamadai, Sarkarsamakulam, Sulthanpet, Valparai, Periyanaickenpalayam and Annur. Secretary of Health and Family Welfare Department P. Senthil Kumar, Coimbatore District Collector Pavankumar G. Giriyappanavar, Coimbatore MP Ganapathy P. Rajkumar, Pollachi MP K. Eswarasamy, Mayor K. Ranganayaki, Corporation Commissioner M. Sivaguru Prabakaran and CMCH Dean A. Nirmala were present. On Sunday morning, the Minister trekked to a few tribal settlements near Kovai Courtallam and got feedback from residents on the reach of Makkalai Thedi Maruthuvam scheme. He also awarded degrees to medical students in the graduation ceremonies held at Coimbatore Medical College and the Government Medical College and ESI Hospital on Sunday.
Time of India
12-06-2025
- Health
- Time of India
Regulating Hope: India's ART Act, Global Best Practices, and the Drive for Research Excellence
Assisted Reproductive Technology ( ART ) has transformed fertility care, bringing renewed hope to countless individuals and couples facing infertility. In response to the growing demand and complexity of ART services, India introduced the Assisted Reproductive Technology (Regulation) Act, 2021—an important step toward creating a safe, ethical, and accountable environment for reproductive treatments. By setting clear standards and oversight mechanisms, the Act lays a strong foundation for responsible practice. As the field continues to evolve, there is an opportunity to build on this progress by enabling a supportive ecosystem for research, innovation, and collaboration—ensuring that India remains responsive to emerging technologies while upholding the rights and well-being of all stakeholders. The ART Act: India's Regulatory Milestone The Assisted Reproductive Technology (Regulation) Act, 2021 was introduced to regulate and supervise ART clinics and banks across India, aiming to prevent misuse and ensure that all procedures are carried out in a safe and ethical manner. To achieve this, the Act established a comprehensive, multi-tiered regulatory framework comprising the National and State ART and Surrogacy Boards , a National Registry, and designated authorities at both the central and state levels. These bodies are responsible for overseeing the registration, functioning, and monitoring of ART clinics and banks, enforcing prescribed standards, and maintaining a central database to support transparency and informed policy-making. Among the Act's key provisions are the mandatory registration of all ART clinics and banks, the requirement for written informed consent from all parties involved, and strict protocols for record-keeping and reporting. Additionally, the Act regulates the sourcing, storage, and handling of gametes, explicitly prohibits sex selection and the commercial sale of gametes or embryos, and includes safeguards to protect the rights and welfare of children born through ART procedures. Together, these measures address a wide range of ethical, medical, and legal concerns, while fostering responsible advancements in the field of reproductive medicine. Global Perspectives United States The US model relies on a combination of federal oversight (primarily through the Centers for Disease Control and Prevention and the Food and Drug Administration) and state-level regulation. Accreditation by professional bodies such as the American Society for Reproductive Medicine (ASRM) and the Society for Assisted Reproductive Technology (SART) ensures high standards of practice and transparent outcome reporting. However, there is significant variability in access and donor anonymity laws across states. Spain Spain is recognized for its progressive, patient-centric approach. The country's national law guarantees broad access to ART, including for single women and same-sex couples. Donor anonymity is strictly enforced, and a comprehensive national registry tracks all procedures and outcomes. Spain's robust oversight has made it a global destination for fertility care. China China's ART sector is tightly regulated by the government, with access limited to married couples. Clinics and banks operate under strict licensing, and there are clear restrictions on embryo storage and use. The centralized approach ensures uniform standards but limits individual choice. Japan Japan's regulatory environment is evolving, with guidelines issued by professional societies and increasing government involvement. Donor anonymity is maintained, and there is a cautious approach to expanding ART services, reflecting societal consensus and ethical considerations. India's take on Research and Innovation India's approach to research and innovation in assisted reproductive technology (ART), including emerging fields like genetic testing and embryo research is evolving. India's in vitro fertilization (IVF) industry is undergoing a significant transformation, driven by rising infertility rates, technological advancements, and increased awareness of fertility treatments. Guidelines and Regulation of ART-Related Research and ICMR India has established regulatory frameworks for ART through the Assisted Reproductive Technology (ART) Act, 2021, and the Surrogacy (Regulation) Act, 2021, which set out ethical and safety standards for ART practices. The ART Act includes strict guidelines on embryo use, prohibiting embryos from being used for purposes other than ART or research, and bans the transfer of gametes/embryos outside India for research or as a source of stem cells. Embryo donation for research is allowed only in specific cases and with written consent. Genetic testing and pre-implantation genetic testing (PGT) are mandated in certain cases to screen embryos for genetic diseases or when medically indicated, reflecting a cautious but proactive approach to integrating new technologies. However, research involving human germline gene therapy, reproductive cloning, and clinical trials with xenogeneic cells is not permitted. In vitro genome modification of embryos (not carried to term) is allowed, but only up to 14 days of fertilization. As of 2025, India does not have specific laws regulating human embryo gene editing. Instead, oversight is provided through guidelines issued by the Indian Council of Medical Research (ICMR). According to the National Guidelines for Stem Cell Research, genome editing—including methods like CRISPR-Cas9—on stem cells, germ-line cells, gametes, or embryos is allowed only for in vitro studies. Such research must be reviewed by the IC-SCR, IEC, and IBSC, and approved by the RCGM. Clinical application of germline gene editing is currently strictly prohibited. Need to Incentivize Research and Innovation There is broad recognition among policymakers and experts of the need to incentivize research and innovation in the medical field, especially in fertility and ART. The government has launched the National Policy on Research and Development and Innovation in Pharma-MedTech Sector and the PRIP (Promotion of Research and Innovation in Pharma MedTech Sector ) scheme, which aims to: Create a regulatory environment that facilitates innovation and research in product private and public investment in innovation through fiscal and non-fiscal industry-academia collaboration and support research in priority areas, including stem cell therapy and complex generics. Nitiz Murdia – Managing Director Indira IVF says, 'Experts and stakeholders in the fertility sector highlight the need for greater awareness, expanded access, insurance coverage, and government-backed initiatives to address India's fertility challenges and to support the growth of ART services and research'. References: This article is written by Nitiz Murdia, Managing Director at Indira IVF (DISCLAIMER: The views expressed are solely of the author and does not necessarily subscribe to it. shall not be responsible for any damage caused to any person/organisation directly or indirectly)
Yahoo
05-06-2025
- Health
- Yahoo
Berry Fertility Launches Revamped App Amid 39% Jump in Egg Freezing Year-on-Year
Created by Fertility Patients, for Fertility Patients — Berry Simplifies IUI, IVF, Egg Freezing, Embryo Transfers, and More SAN FRANCISCO, June 05, 2025--(BUSINESS WIRE)--Berry Fertility, a leading patient fertility management platform, today announced a revamped app with a powerful suite of new features designed to simplify and support every stage of the fertility journey, from IUI and IVF, to egg freezing and embryo transfers. Fertility care is in high demand and short supply. Egg freezing cycles have more than doubled in the past five years, and each new year shows record-breaking growth. The Society for Assisted Reproductive Technology's most recent official data shows a surge in egg freezing cycles of 39.2%, the biggest single-year numerical jump on record.* Yet Assisted Reproductive Technology (ART) services like IVF still meet less than 30% of patient needs. Berry Fertility is helping bridge this access gap with a platform that puts personalized, tech-enabled fertility support in every patient's pocket. With this new rollout, Berry customers can: Access Step-by-Step Treatment Guides: Understand what to expect from IUI, IVF, egg freezing, embryo transfers, and timed intercourse with simplified breakdowns of complex care plans. Manage Medications: Organize medications and dosing instructions more easily and confidently, with access to clear medical information and how-tos. To date, Berry has delivered over 200,000 medication reminders. Smartly Add Medications: Use the phone's camera to quickly scan dozens of medications to import into the app. Track Appointments, Symptoms, Lab Results, Milestones, and Reminders: Stay on top of everything — from ultrasound dates to medication times — with a custom fertility calendar. Track symptoms and store lab results to support more informed conversations with providers. Access a Library of In-Depth Resources: Get a heads-up on what to expect and receive helpful resources at every stage of treatment, including articles, protocol diagrams, videos, common FAQ, and a fertility glossary. Share With Your Support Network: Share a fertility treatment with anyone — a partner, parent, or friend — so they can follow along or provide support. Talk to an Expert Anytime: Chat with the Berry team anytime for help with treatment questions, tech issues, or emotional support. "Our team at Berry is made up of patients who have gone through fertility treatments themselves," said Irene Alvarado, co-founder and CEO of Berry Fertility. "We built Berry to be the tool we all wished we had — something that makes fertility care more accessible, less stressful, and a whole lot more human." Berry is available in all 50 U.S. states, Mexico, Australia, and Canada, and currently holds a five-star rating in the App Store, far above the industry standard of 2.4 stars. The app offers both a free tier and a premium version for $9.99/month or $72/year. To learn more, visit To make a request for feature improvements, partner, or get in touch, reach out to hello@ About Berry Fertility Berry Fertility is a comprehensive patient management platform for IVF, IUI, embryo transfer, and egg freezing. Started in 2022 by a team of Google alumni, Berry Fertility streamlines fertility treatments for both patients and clinics. Through the platform, patients benefit from a seamless onboarding process, digital scheduling, and access to vital educational resources. Providers, meanwhile, can automate administrative tasks so they can get back to patient care. For more information visit, *Official SART data published in the latest official report published in 2025, tallying 2023 data. View source version on Contacts Irene Alvarado, press@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
05-06-2025
- Health
- Business Wire
Berry Fertility Launches Revamped App Amid 39% Jump in Egg Freezing Year-on-Year
SAN FRANCISCO--(BUSINESS WIRE)-- Berry Fertility, a leading patient fertility management platform, today announced a revamped app with a powerful suite of new features designed to simplify and support every stage of the fertility journey, from IUI and IVF, to egg freezing and embryo transfers. Fertility care is in high demand and short supply. Egg freezing cycles have more than doubled in the past five years, and each new year shows record-breaking growth. The Society for Assisted Reproductive Technology's most recent official data shows a surge in egg freezing cycles of 39.2%, the biggest single-year numerical jump on record.* Yet Assisted Reproductive Technology (ART) services like IVF still meet less than 30% of patient needs. Berry Fertility is helping bridge this access gap with a platform that puts personalized, tech-enabled fertility support in every patient's pocket. With this new rollout, Berry customers can: Access Step-by-Step Treatment Guides: Understand what to expect from IUI, IVF, egg freezing, embryo transfers, and timed intercourse with simplified breakdowns of complex care plans. Manage Medications: Organize medications and dosing instructions more easily and confidently, with access to clear medical information and how-tos. To date, Berry has delivered over 200,000 medication reminders. Smartly Add Medications: Use the phone's camera to quickly scan dozens of medications to import into the app. Track Appointments, Symptoms, Lab Results, Milestones, and Reminders: Stay on top of everything — from ultrasound dates to medication times — with a custom fertility calendar. Track symptoms and store lab results to support more informed conversations with providers. Access a Library of In-Depth Resources: Get a heads-up on what to expect and receive helpful resources at every stage of treatment, including articles, protocol diagrams, videos, common FAQ, and a fertility glossary. Share With Your Support Network: Share a fertility treatment with anyone — a partner, parent, or friend — so they can follow along or provide support. Talk to an Expert Anytime: Chat with the Berry team anytime for help with treatment questions, tech issues, or emotional support. 'Our team at Berry is made up of patients who have gone through fertility treatments themselves,' said Irene Alvarado, co-founder and CEO of Berry Fertility. 'We built Berry to be the tool we all wished we had — something that makes fertility care more accessible, less stressful, and a whole lot more human.' Berry is available in all 50 U.S. states, Mexico, Australia, and Canada, and currently holds a five-star rating in the App Store, far above the industry standard of 2.4 stars. The app offers both a free tier and a premium version for $9.99/month or $72/year. To learn more, visit To make a request for feature improvements, partner, or get in touch, reach out to hello@ About Berry Fertility Berry Fertility is a comprehensive patient management platform for IVF, IUI, embryo transfer, and egg freezing. Started in 2022 by a team of Google alumni, Berry Fertility streamlines fertility treatments for both patients and clinics. Through the platform, patients benefit from a seamless onboarding process, digital scheduling, and access to vital educational resources. Providers, meanwhile, can automate administrative tasks so they can get back to patient care. For more information visit, *Official SART data published in the latest official report
